keyword
MENU ▼
Read by QxMD icon Read
search

Angiotensin receptor blocker

keyword
https://www.readbyqxmd.com/read/28215000/angiotensin-ii-receptor-blockers-attenuate-lipopolysaccharide-induced-memory-impairment-by-modulation-of-nf-%C3%AE%C2%BAb-mediated-bdnf-creb-expression-and-apoptosis-in-spontaneously-hypertensive-rats
#1
Ruby Goel, Shahnawaz Ali Bhat, Kashif Hanif, Chandishwar Nath, Rakesh Shukla
Clinical studies demonstrated a positive correlation between hypertension and cognitive decline. Beneficial effects of angiotensin II receptor blockers on cognitive functions have also been reported earlier; however, its role in chronic neuroinflammation-induced memory impairment in the hypertensive state is not well understood. Therefore, in the present study, we investigated the effect of angiotensin II receptor blockers on memory impairment induced by lipopolysaccharide (LPS) in spontaneously hypertensive rats (SHRs)...
February 18, 2017: Molecular Neurobiology
https://www.readbyqxmd.com/read/28209222/roles-of-angiotensin-peptides-and-recombinant-human-ace2-in-heart-failure
#2
Ratnadeep Basu, Marko Poglitsch, Haran Yogasundaram, Jissy Thomas, Brian H Rowe, Gavin Y Oudit
BACKGROUND: The renin-angiotensin system (RAS) is activated in heart failure (HF) and inhibition of RAS is a mainstay therapy for HF. Angiotensin-converting enzyme 2 (ACE2) and its product, angiotensin 1-7 (Ang-[1-7]), are important negative regulators of the RAS. OBJECTIVES: A comprehensive examination of angiotensin peptide levels and therapeutic effects of recombinant human ACE2 (rhACE2) on peptide metabolism was evaluated in human plasma and explanted heart tissue from patients with HF...
February 21, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28207279/angiotensin-converting-inhibitors-and-angiotensin-ii-receptor-blockers-and-longitudinal-change-in-percent-emphysema-on-computed-tomography-the-mesa-lung-study
#3
Megha A Parikh, Carrie P Aaron, Eric A Hoffman, Joseph E Schwartz, Jaime Madrigano, John H M Austin, Ravi Kalhan, Gina Lovasi, Karol Watson, Karen Hinckley Stukovsky, R Graham Barr
RATIONALE: Chronic obstructive pulmonary disease (COPD) is the third-leading cause of death in the United States. Emphysema on computed tomography (CT) is associated with increased morbidity and mortality in patients with and without spirometrically defined COPD but no available medications target emphysema.  Transforming growth factor beta (TGF-β) and endothelial dysfunction are implicated in emphysema pathogenesis, and angiotensin II receptor blockers (ARB) inhibit TGF-β, improve endothelial function and restore airspace architecture in murine models...
February 16, 2017: Annals of the American Thoracic Society
https://www.readbyqxmd.com/read/28203527/superoxide-increases-angiotensin-ii-at1-receptor-function-in-human-kidney-2-cells
#4
Mohammad Saleem, Indira Pokkunuri, Mohammad Asghar
The redox-sensitive Sp family transcription factor has been linked to the regulation of angiotensin II type 1 receptor (AT1R). However, the exact mechanism of AT1R regulation in renal cells is poorly understood. We tested the specificity of reactive oxygen species (ROS), superoxide vs. hydrogen peroxide (H2O2), and the specific role of Sp3 transcription factor, if any, in the regulation of AT1R in human kidney cells (HK2 cells). Superoxide dismutase (SOD) inhibitor diethyldithiocarbamate (DETC), but not H2O2 treatment, increased fluorescence levels of superoxide probe dihydroethidium (DHE)...
December 2016: FEBS Open Bio
https://www.readbyqxmd.com/read/28202884/neurohumoral-modulation-during-waon-therapy-in-chronic-heart-failure%C3%A3-subanalysis-of-waon-chf-study
#5
Tomoko Ichiki, John C Burnett, Christopher G Scott, Denise M Heublein, Masaaki Miyata, Koichiro Kinugawa, Teruo Inoue, Chuwa Tei
BACKGROUND: Heart failure (HF) is a disease of neurohumoral dysfunction and current pharmacological therapies for HF have not improved mortality rates, thus requiring additional new strategies. Waon therapy for HF patients may be a complementary strategy with peripheral vasodilation via nitric oxide. We hypothesized that Waon therapy would improve neurohumoral factors, such as natriuretic peptides (NP) and the renin-angiotensin-aldosterone system (RAAS) in HF.Methods and Results:Plasma samples were collected from patients enrolled in the WAON-CHF Study (Waon therapy (n=77) or control (n=73)) before and after the treatment...
February 16, 2017: Circulation Journal: Official Journal of the Japanese Circulation Society
https://www.readbyqxmd.com/read/28202167/acute-changes-in-glomerular-filtration-rate-with-renin-angiotensin-system-ras-inhibition-clinical-implications
#6
Matthew R Weir
Renin-angiotensin system inhibition with either angiotensin-converting enzyme inhibitors or angiotensin receptor blockers has been shown to be effective in reducing progression of renal and cardiovascular disease. However, these medications are often associated with an initial reduction of estimated glomerular filtration rate, which is thought to be functional but may be of clinical significance. Newer insights from secondary analyses of large clinical trials may provide important clinical perspective.
March 2017: Kidney International
https://www.readbyqxmd.com/read/28195517/systematic-underutilisation-of-secondary-preventive-drugs-in-patients-with-acute-coronary-syndrome-and-reduced-renal-function
#7
Masih Khedri, Karolina Szummer, Juan-Jesus Carrero, Tomas Jernberg, Marie Evans, Stefan H Jacobson, Jonas Spaak
Aims The high risk of recurrent events in patients with reduced renal function following an acute coronary syndrome (ACS) may in part be due to suboptimal secondary prevention. We aimed to describe the association between renal dysfunction and the prescription, initiation and persistent use of secondary prevention during the first year after a first ACS. Methods We identified all patients admitted to any Swedish coronary care unit for a first ACS between 2005 and 2010 ( n = 77,432). In 75,129 patients, creatinine levels were available in order to obtain the estimated glomerular filtration rate (eGFR)...
January 1, 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28191524/renin-angiotensin-aldosterone-system-in-insulin-resistance-and-metabolic-syndrome
#8
Undurti N Das
Obesity and its consequent complications such as hypertension and metabolic syndrome are increasing in incidence in almost all countries. Insulin resistance is common in obesity. Renin- angiotensin system (RAS) is an important target in the treatment of hypertension and drugs that act on RAS improve insulin resistance and decrease the incidence of type 2 diabetes mellitus, explaining the close association between hypertension and type 2 diabetes mellitus. RAS influences food intake by modulating the hypothalamic expression of neuropeptide Y and orexins via AMPK dephosphorylation...
June 1, 2016: Journal of Translational Internal Medicine
https://www.readbyqxmd.com/read/28186357/short-and-long-term-outcomes-with-renin-angiotensin-aldosterone-inhibitors-in-renal-transplant-recipients-a-meta-analysis-of-randomized-controlled-trials
#9
Ruo-Xi Liao, Xia-Fei Lyu, Wen-Jiao Tang, Kai Gao
BACKGROUND: Angiotensin-convertingenzyme inhibitors (ACEIs) and angiotensin II receptor type 1 blockers (ARBs) are often prescribed for renal transplant recipients (RTRs), but the outcomes of these medications in RTRs remain controversial. METHODS: The PubMed, Embase, and Cochrane Library databases were systematically searched. Randomized controlled trials investigating the outcomes of ACEI/ARBs in RTRs were included for meta-analysis. RESULTS: Twenty-two trials with 2242 patients were identified...
February 10, 2017: Clinical Transplantation
https://www.readbyqxmd.com/read/28185171/neprilysin-inhibitors-in-cardiovascular-disease
#10
REVIEW
Guson Kang, Dipanjan Banerjee
Mortality from heart failure remains high despite advances in medical therapy over the last three decades. Angiotensin receptor-neprilysin inhibitor (ARNI) combinations are the latest addition to the heart failure medical armamentarium, which is built on the cornerstone regimen of beta blockers, angiotensin converting enzyme (ACE) inhibitors/angiotensin receptor blockers, and aldosterone antagonists. Recent trial data have shown a significant mortality benefit from ARNIs, which, as of May 2016, have now received a class I recommendation for use in patients with heart failure and reduced ejection fraction from the major American and European cardiology societies...
February 2017: Current Cardiology Reports
https://www.readbyqxmd.com/read/28179398/medical-therapy-for-secondary-prevention-and-long-term-outcome-in-patients-with-myocardial-infarction-with-non-obstructive-coronary-artery-minoca-disease
#11
Bertil Lindahl, Tomasz Baron, David Erlinge, Nermin Hadziosmanovic, Anna M Nordenskjöld, Anton Gard, Tomas Jernberg
Background -Myocardial infarction (MI) with non-obstructive coronary arteries (MINOCA) occurs in 5-10% of all patients with MI. Clinical trials of secondary prevention treatment in MINOCA patients are lacking. Therefore, the aim of this study was to examine the associations between treatment with statins, renin-angiotensin system blockers, beta-blockers, dual antiplatelet therapy and long-term cardiovascular events. Methods -Observational study of MINOCA patients recorded in the SWEDEHEART registry between July 2003 and June 2013 and followed until December 2013 for outcome events in the Swedish Cause of Death Register and National Patient Register...
February 8, 2017: Circulation
https://www.readbyqxmd.com/read/28177196/end-stage-renal-disease-and-adherence-to-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-among-patients-with-diabetes
#12
Michal Shani, Shlomo Vinker, Leonid Feldman
Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) have become standards of care for diabetic nephropathy. The authors assessed the association between treatment adherence to ACEIs and ARBs and the development of end-stage renal disease (ESRD). The cohort comprised the 9895 members of the Central District of Clalit Health Services aged 40 to 70 years, diagnosed with diabetes before 2002, who filled at least four ACEI or ARB monthly prescriptions during 2002-2011. Forty-six percent of patients made 10 or more purchases a year...
February 8, 2017: Journal of Clinical Hypertension
https://www.readbyqxmd.com/read/28176630/novel-drugs-for-hypertension-and-heart-failure-struggling-for-a-place-under-the-sun
#13
Charles Faselis, Chrysoula Boutari, Michael Doumas, Konstantinos Imprialos, Konstantinos Stavropoulos, Peter Kokkinos
BACKGOUND: Current drug therapy for the management of arterial hypertension and heart failure has provided substantial benefits but has also some limitations. LCZ696, a dual inhibitor of angiotensin receptor blockers and neprilysin, and finerenone, a non-steroidal mineralocorticoid receptor antagonist, are two recently developed novel agents for the management of these conditions. METHODS: This review aims to present the pathophysiological basis for the use of these two novel drugs, critically discuss available clinical data, and provide future perspectives...
February 6, 2017: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/28176581/correction
#14
(no author information available yet)
There was an error in our CPD article Chronic heart failure part 2: treatment and management (11 January). On page 55, the first sentence in the angiotensin receptor neprilysin inhibitor section should read: Valsartan with sacubitril is an angiotensin receptor neprilysin inhibitor that has recently been approved for use as a replacement for ACE inhibitors, to further reduce the risk of hospitalisation and death in ambulatory patients with heart failure and an ejection fraction ≤35% who remain symptomatic despite optimal treatment with an ACE inhibitor, a beta-blocker and an aldersterone antagonist (Ponikowski et al 2016)...
February 8, 2017: Nursing Standard
https://www.readbyqxmd.com/read/28169115/angiotensin-ii-antagonism-is-associated-with-reduced-risk-for-gastrointestinal-bleeding-caused-by-arteriovenous-malformations-in-patients-with-left-ventricular-assist-devices
#15
Brian A Houston, Andrea L C Schneider, Joban Vaishnav, David M Cromwell, P Elliott Miller, Kamil F Faridi, Ashish Shah, Chris Sciortino, Glenn Whitman, Ryan J Tedford, Gerin R Stevens, Daniel P Judge, Stuart D Russell, Rosanne Rouf
BACKGROUND: Angiogenesis is implicated in formation of gastrointestinal arteriovenous malformations (AVMs). Angiotensin II signaling is involved in angiogenesis through the vascular endothelial growth factor (VEGF) and angiopoietin-2 pathways. We hypothesized that angiotensin-converting enzyme inhibitor (ACEI) and angiotensin receptor blocker (ARB) therapy would be associated with a reduced risk of all-cause gastrointestinal bleeding (GIB) and AVM-associated GIB in patients with left ventricular assist devices (LVADs)...
December 30, 2016: Journal of Heart and Lung Transplantation
https://www.readbyqxmd.com/read/28166592/renin-angiotensin-system-blockade-improves-cardiac-indices-in-acromegaly-patients
#16
Julia D J Thomas, Abhishek Dattani, Filip Zemrak, Thomas Burchell, Scott A Akker, Felicity J L Kaplan, Bernard Khoo, Simon Aylwin, Ashley B Grossman, L Ceri Davies, Márta Korbonits
Blockade of the angiotensin-renin system, with angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs), has been shown to improve cardiac outcomes following myocardial infarction and delay progression of heart failure. Acromegaly is associated with a disease-specific cardiomyopathy, the pathogenesis of which is poorly understood.The cardiac indices of patients with active acromegaly with no hypertension (Group A, n=4), established hypertension not taking ACEi/ARBs (Group B, n=4) and established hypertension taking ACEi/ARBs (Group C, n=4) were compared using cardiac magnetic imaging...
February 6, 2017: Experimental and Clinical Endocrinology & Diabetes
https://www.readbyqxmd.com/read/28157068/clinical-and-pathological-characteristics-of-fabry-disease-combined-with-iga-nephropathy-in-chinese-patients%C3%A2
#17
Nannan Yang, Xia Wang, Feng Xu, Caihong Zeng, Jinquan Wang, Zhihong Liu
AIMS: To improve diagnosis and treatment, we characterized Fabry disease combined with IgA nephropathy and its response to treatment clinically and pathologically in Chinese patients. MATERIALS AND METHODS: Clinical and pathological characteristics of 6 Chinese patients with renal biopsy-proven Fabry disease combined with IgA nephropathy were retrospectively analyzed. RESULTS: There were 4 males and 2 females in this study. All of the 6 patients presented with proteinuria...
February 3, 2017: Clinical Nephrology
https://www.readbyqxmd.com/read/28155610/mineralocorticoid-antagonists-in-esrd-an-overview-of-their-efficacy-and-safety
#18
Panagiotis I Georgianos, Vasilios Vaios, Theodoros Eleftheriadis, Pantelis Zebekakis, Vassilios Liakopoulos
Add-on mineralocorticoid-receptor-antagonists (MRAs) spironolactone and eplerenone can enhance the cardioprotective action of angiotensin-converting-enzyme-inhibitors (ACEIs), angiotensin-receptor-blockers (ARBs) and/or β-blockers in non-dialysis patients with congestive heart failure (CHF) and reduced left ventricular (LV) ejection fraction. The efficacy and safety of MRAs among patients on chronic dialysis is less well studied. A growing body of evidence derived from small randomized studies suggests that MRA therapy may improve a number of surrogate cardiovascular (CV) risk factors (i...
February 1, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28146207/multiprofessional-treatment-of-high-blood-pressure-in-very-elderly-patients
#19
Luciana Muniz Sanches Siqueira Veiga Jardim, Thiago Veiga Jardim, Weimar Kunz Sebba Barroso de Souza, Camila Dutra Pimenta, Ana Luiza Lima Sousa, Paulo César Brandão Veiga Jardim
BACKGROUND: As the world population ages, patients older than 80 years, known as very elderly, are more frequently found. There are no studies in this age group aimed at analyzing the multidisciplinary intervention in the treatment of systemic arterial hypertension (SAH) and some comorbidities. OBJECTIVES: To assess the effect of a multidisciplinary approach in very elderly hypertensives cared for at a specialized service. METHODS: Longitudinal retrospective cohort study in a multidisciplinary service specialized in the SAH treatment in the Brazilian West-Central region...
January 2017: Arquivos Brasileiros de Cardiologia
https://www.readbyqxmd.com/read/28146117/anti-fibrotic-effect-of-losartan-an-angiotensin-ii-receptor-blocker-is-mediated-through-inhibition-of-er-stress-via-up-regulation-of-sirt1-followed-by-induction-of-ho-1-and-thioredoxin
#20
Hyosang Kim, Chung Hee Baek, Raymond Bok Lee, Jai Won Chang, Won Seok Yang, Sang Koo Lee
Endoplasmic reticulum (ER) stress is increasingly identified as modulator of fibrosis. Losartan, an angiotensin II receptor blocker, has been widely used as the first choice of treatment in chronic renal diseases. We postulated that anti-fibrotic effect of losartan is mediated through inhibition of ER stress via SIRT1 (silent mating type information regulation 2 homolog 1) hemeoxygenase-1 (HO-1)/thioredoxin pathway. Renal tubular cells, tunicamycin (TM)-induced ER stress, and unilateral ureteral obstruction (UUO) mouse model were used...
January 31, 2017: International Journal of Molecular Sciences
keyword
keyword
10488
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"